Nancy L Lewis
Overview
Explore the profile of Nancy L Lewis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
561
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Denlinger C, Meropol N, Li T, Lewis N, Engstrom P, Weiner L, et al.
Clin Colorectal Cancer
. 2014 Feb;
13(2):81-6.
PMID: 24512954
Background: Patients with advanced biliary tract cancers have limited therapeutic options. Preclinical data suggest that proteasome inhibition may be an effective therapeutic strategy. We thus evaluated the clinical efficacy of...
2.
Connor J, Cristea M, Lewis N, Lewis L, Komarnitsky P, Mattiacci M, et al.
BMC Cancer
. 2013 Jan;
13:20.
PMID: 23320927
Background: Humanized KS-interleukin-2 (huKS-IL2), an immunocytokine with specificity for epithelial cell adhesion molecule (EpCAM), has demonstrated favorable tolerability and immunologic activity as a single agent. Methods: Phase 1b study in...
3.
Marshall J, Hwang J, Eskens F, Burger H, Malik S, Uttenreuther-Fischer M, et al.
Invest New Drugs
. 2012 Nov;
31(2):399-408.
PMID: 23161335
Background: A Phase I study to determine the maximum tolerated dose (MTD) and pharmacokinetics of afatinib (BIBW 2992), a novel irreversible ErbB Family Blocker, administered orally once daily in a...
4.
Gerecitano J, Stephenson J, Lewis N, Osmukhina A, Li J, Wu K, et al.
Invest New Drugs
. 2012 May;
31(2):355-62.
PMID: 22615058
Background: This Phase I study assessed the safety and maximum tolerated dose (MTD) of the kinesin spindle protein inhibitor AZD4877 in patients with relapsed/refractory solid tumors and lymphoma. Methods: In...
5.
Spratlin J, Cohen R, Eadens M, Gore L, Camidge D, Diab S, et al.
J Clin Oncol
. 2010 Jan;
28(5):780-7.
PMID: 20048182
PURPOSE To evaluate the safety, maximum-tolerated dose (MTD), pharmacokinetics (PKs), pharmacodynamics, and preliminary anticancer activity of ramucirumab (IMC-1121B), a fully human immunoglobulin G(1) monoclonal antibody targeting the vascular endothelial growth...
6.
Lewis N, Lewis L, Eder J, Reddy N, Guo F, Pierce K, et al.
J Clin Oncol
. 2009 Sep;
27(31):5262-9.
PMID: 19738123
Purpose: This phase I, first-in-human study evaluated the safety, tolerability, pharmacokinetics, and maximum-tolerated dose (MTD) of an oral platelet-derived growth factor receptor inhibitor, CP-868,596. Patients And Methods: Patients with advanced...
7.
Lewis N, Brismee J, James C, Sizer P, Sawyer S
Arch Phys Med Rehabil
. 2009 Mar;
90(3):454-62.
PMID: 19254611
Objective: To evaluate the effect of stretching on the parameters of postural sway and on the kinematic variables associated with balance control in women and men. Design: Mixed repeated measures...
8.
Koch K, Reddy N, Cohen R, Lewis N, Whitehead B, Mackay K, et al.
J Clin Oncol
. 2009 Feb;
27(8):1191-6.
PMID: 19188677
Purpose: This study was conducted to characterize the effect of food on the relative bioavailability of lapatinib. Patients And Methods: A single 1,500-mg, oral dose of lapatinib was administered to...
9.
Ettinger D, Agulnik M, Cristea M, Eaton K, Fidias P, Gockerman J, et al.
J Natl Compr Canc Netw
. 2009 Jan;
6(10):1026-60.
PMID: 19176200
No abstract available.
10.
Cohen S, Engstrom P, Lewis N, Langer C, McLaughlin S, Beard M, et al.
Am J Clin Oncol
. 2008 Apr;
31(1):1-5.
PMID: 18376220
Purpose: The combination of capecitabine and oxaliplatin has clinical benefit in a variety of gastrointestinal malignancies. The proteasome inhibitor bortezomib enhances the cytotoxic activity of fluoropyrimidines and platinum agents in...